EBR Online 2017: Diabetes

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Diabetes

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 3.50 ABIM MOC
  • 3.50 AMA PRA Category 1 Credits
  • 3.50 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 3.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 3.50 ABIM MOC
  • 3.50 AMA PRA Category 1 Credits
  • 3.50 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Adrenal

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Adrenal

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Obesity/Lipids

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Obesity/Lipids

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Pituitary

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Pituitary

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Female Reproduction

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Female Reproduction

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.25 ABIM MOC
  • 1.25 AMA PRA Category 1 Credits
  • 1.25 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.25 ABIM MOC
  • 1.25 AMA PRA Category 1 Credits
  • 1.25 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Male Reproduction

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Male Reproduction

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.25 ABIM MOC
  • 1.25 AMA PRA Category 1 Credits
  • 1.25 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.25 ABIM MOC
  • 1.25 AMA PRA Category 1 Credits
  • 1.25 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Calcium & Bone

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Calcium & Bone

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

EBR Online 2017: Thyroid

Welcome to the EBR Online 2017 Evaluation Page

Click the button below to begin the recordings activity.  At the conclusion of the session activity the access code for this course will be displayed.  Return here and enter the access code in the space provided to evaluate the activity, and claim credits commensurate with your participation.

Go to EBR Thyroid Activity

Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have the opportunities to review questions asked to the faculty, compare results from other participants, and read detailed answer explanations, references, and a customized score report.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Discuss the treatment options for hyperthyroidism
  • Explain the risks and benefits of antithyroid drugs
  • Discuss potential cardiovascular risks of subclinical hyperthyroidism
  • Describe the preoperative imaging needed for papillary thyroid cancer
  • Identify thyroid cancer patients to consider for systemic therapy
  • Describe the effect of iodine deficiency and mild maternal thyroid hypofunction on fetal development
  • List the causes of persistent hypothyroidism in patients on L-thyroxine
  • Explain the effect of genetic variations on thyroid hormone replacement
  • Improve understanding of the risks and possible benefits of T4:T3 therapy
  • Diagnose and manage hyperthyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Surgery
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation
Course opens: 
09/28/2017
Course expires: 
09/28/2020
Rating: 
No votes yet
0

Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine

Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine

Medical Editor  
Abbie L. Young, MS, CGC, ELS(D)

Disclosure Policy

The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma

Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.

Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals

Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals

Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono

The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.75 ABIM MOC
  • 1.75 AMA PRA Category 1 Credits
  • 1.75 CME Certificate of Participation

Accreditation Period

Course opens: 
09/28/2017
Course expires: 
09/28/2020

Access the evaluation through this tab.  To start, users must...

1.  Be logged into personal Endocrine Society account

     This can be done through the Login button above or in the top right corner of the page.

     When logged in, you will see your name in the blue ribbon at the top of the page.

2.  Enter the evaluation access code which is available at the conclusion of EBR 2017 session recordings

3.  After completing steps 1 & 2 click the blue Start button to begin the evaluation

Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline Educational Activity

Background:

Throughout recorded history (in absence of an endocrine disorder) some men and women have experienced confusion and anguish resulting from rigid, forced conformity to sexual dimorphism. The 20th century marked the emergence of a social awakening for more awareness, research and medical intervention for gender-incongruent persons.

Gender-affirmation is a multidisciplinary treatment in which endocrinologists play an important role. This update to the 2009 Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline, updates the diagnostic classification, recommendations regarding children, surgery, monitoring and patient education.

Within this activity you will hear from the task force members regarding the latest recommendations and assess what you have learned in 5 short modules.

  • New Scientific Evidence 
  • Management of Transgender Children and Adolescents
  • Monitoring and Surveillance
  • Surgery and Follow-up Management
  • Guideline Summary

Introduction to Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline by Wylie C. Hembree, MD

    TARGET AUDIENCE

    This content is for physicians and healthcare professionals seeking to remain up to date on the latest recommendations made by the Society for endocrine treatment of Gender-Dysphoric/ Gender-Incongruent patients.

    LEARNING OBJECTIVES 

    By the end of this session, participants will be able to:

    1. List significant changes in the evidence base for Gender Dysphoria /Gender Incongruence since publication of the previous ES guideline on this topic.
    2. Define significant changes in best practices that are being recommended in the 2017 Gender Dysphoria/Gender Incongruence guideline due to changes in science.
    3. Identify gaps in the existing evidence base for Gender Dysphoria /Gender Incongruence which contribute to controversy or disagreement among clinicians about standards for optimal patient care.

      Additional Information

      Target Audience: 
      Physician-in-practice
      Fellow
      Resident
      Clinical researcher
      Scientific researcher
      Educator/Teacher
      Pharmacist
      Nurse/Nurse practitioner
      Physician assistant
      Allied health professional
      Other
      Competency Area: 
      Patient Care and Procedural Skills
      Medical Knowledge
      Interpersonal and Communication Skills
      Topic Area: 
      Quality Improvement and Healthcare Delivery
      General Endocrinology
      Hormone Abuse
      Men’s Health
      Pediatric Endocrinology
      Surgery
      Women’s Health
      Level of Outcomes: 
      Level 1 (Participation)
      Level 2 (Satisfaction)
      Level 3A (Learning: Declarative Knowledge (Knows))
      Level 3B (Learning: Procedural Knowledge (Knows How))
      Activity summary
      Available credit: 
      • 1.00 ABIM MOC
      • 1.00 ABP MOC
      • 1.00 AMA PRA Category 1 Credits
      • 1.00 CME Certificate of Participation
      Course opens: 
      08/11/2017
      Course expires: 
      09/15/2019
      Rating: 
      No votes yet
      0

      Wylie C. Hembree, MD
      Chair

      Associate Attending Physician
      New York Presbyterian Hospital
      Endocrinology, Diabetes & Metabolism

      Peggy T. Cohen-Kettenis, PhD
      Professor Emeritus
      Department of Medical Psychology
      VU University Medical Center, Amsterdam

      Stephen M. Rosenthal, MD
      Professor of Pediatrics
      Division of Pediatric Endocrinology
      Medical Director, Child and Adolescent Gender Center
      Benioff Children's Hospital
      University of California San Francisco

      Joshua D. Safer, MD
      Associate Professor of Medicine and Molecular Medicine
      Boston University School of Medicine
      Center for Endocrinology, Diabetes, Nutrition & Weight Management

      Vin Tangpricha, MD, PhD
      Associate Professor of Medicine
      Director of Fellowship Program
      Emory University School of Medicine

      STATEMENT OF INDEPENDENCE

      As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

      DISCLOSURE POLICY

      The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

      The following GD/GI Task Force members reported relevant financial relationships:

      Stephen M. Rosenthal, MD: Advisory Board, AbbVie

      Vin Tangpricha, MD, PhD: Grantee, Cystic Fibrosis Foundation, National Institutes of Health

      The following GD/GI Task Force members reported no relevant financial relationships:

      Wylie C. Hembree, MD; Peggy T. Cohen-Kettenis, PhD; Joshua D. Safer, MD

      Disclosure information for presenters is included in their individual recorded presentations.

      Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

      DISCLAIMERS

      USE OF PROFESSIONAL JUDGMENT:

      The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

      DRUGS AND DOSAGES:

      When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

      POLICY ON UNLABELED/OFF-LABEL USE

      The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

      PRIVACY AND CONFIDENTIALITY STATEMENT

      The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

      ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

      This activity is not supported by educational grant(s) or other funds from any commercial supporter.

      Accreditation Statement

      The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

      The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
       

      Maintenance of Certification

      Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) and American Board of Pediatric's Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM and ABP MOC credit.

      Available Credit

      • 1.00 ABIM MOC
      • 1.00 ABP MOC
      • 1.00 AMA PRA Category 1 Credits
      • 1.00 CME Certificate of Participation

      Accreditation Period

      Course opens: 
      08/11/2017
      Course expires: 
      09/15/2019

      Click "Start" to begin this free educational activity. You will need to login using your Endocrine Society login credentials. If you forgot your login information feel free to live chat with a the Society to assist you. If you do not have a login, you may create a complimentary account on the login page.

      Diabetes Diagnosis & Management Online 2017

      Target Audience

      Target audience: 

      This program should be of substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

      Learning Objectives

      Learning objectives: 

      Upon completion of this educational activity, learners will be able to:

      Where Diabetes Technology Is and Where It’s Going

      • Discuss the current landscape of available technologies in the management of diabetes
      • Recognize the need for patient education to ensure successful use of technology in the personal management of diabetes

      Novel Therapies for Type 2 Diabetes

      • Discuss the current landscape of available therapies in the management of T2D and the clinical impact of each
      • Review the effectiveness and utility of novel GLP1 agonist, and choose patients who are most appropriate for this class of medicines
      • Identify appropriate candidates for insulin pump therapy and/or continuous glucose monitor system with T2D

      NASH/NAFLD                                                                                                                                        

      • Screen patients for early clinical signs of NAFLD
      • Recognize the behavioral approaches to NAFLD management that are most impactful in practice
      • Select appropriate medical therapy options for the management of NAFLD in patients with T2D

      Changing the Paradigm of Diabetes Prevention to Treating Pre-diabetes

      • Develop an approach to choosing a treatment strategy that is most optimal for managing pre-diabetes
      • Recognize the behavioral approaches to pre-diabetes management that are most impactful in practice
      • Explain the methods available for promoting lasting behavior change

      Pediatric Diabetes                                                                  

      • Discuss the evolving prevalence of T1D and T2D in pediatric patients
      • Determine the most effect treatment strategies for managing diabetes in children
      • Recognize pediatric-specific barriers to compliance and recommend strategies to overcome them
      • Utilize insulin-dosing guidelines to adjust insulin regimen

      The Statin Intolerant Patient

      • Identify blood pressure treatment targets and preferred pharmacologic treatment options for patients with diabetes
      • Describe the effectiveness of various classes of lipid-modifying therapies for CVD treatment and prevention in T2D

      Treatment of Diabetes in the Older Adult

      • Recognize geriatric syndromes that increase risk for hypoglycemia
      • Modify glycemic goals in elderly patients at high risk for hypoglycemia
      • Recognize the appropriate medical management strategy to improve glycemic control in the elderly

      CGM in 2017

      • Identify appropriate candidates for continuous glucose monitor system with type 1 or type 2 diabetes

      Treatment of Hyperglycemia: Combination vs. Sequential Therapy

      • Determine the most effect strategies to advance therapy when managing hyperglycemia
      • Recognize patient barriers to compliance and suggest strategies to overcome them
      • Utilize insulin-dosing guidelines to adjust insulin regimen
      • Select therapies to manage hyperglycemia that takes patient factors into consideration

      Modern Management of Type 1 Diabetes

      • Discuss the advances in stem cell and immunology research in T1D
      • Describe options for incorporating new therapies beyond insulin
      • Identify appropriate candidates for insulin pump therapy and/or continuous glucose monitor system
      • Recognize the need for patient education to ensure successful use of technology in the personal management of T1D

      Can an Endocrinologist Improve Cardiovascular Outcomes through Glucose-Lowering Medications?

      • Summarize the most recent guideline recommendations for screening coronary artery disease in T2D including specific goals in reducing risk factors and appropriate biochemical targets
      • Explain cardiovascular complications, risk factors, screening guidelines, and recommended therapies for cardiovascular risk reduction for patients with T2D
      • Integrate new studies on cardiovascular outcomes trials into practice by incorporating cardiovascular considerations when selecting therapy for patients with T2D
      • Recognize practical implications of recent findings in EMPA-REG and LEADER trials on current treatment algorithms and future clinical studies

      Therapeutic Strategies in Gestational Diabetes to Halt Type 2 Risk in Mom and Obesity in Offspring

      • Screen patients for early clinical signs of gestational diabetes using recent guidelines
      • Select appropriate medical therapy options for the management of gestational diabetes
      • Devise a follow-up plan for postpartum monitoring of patients with gestational diabetes

      Additional Information

      Target Audience: 
      Physician-in-practice
      Fellow
      Resident
      Clinical researcher
      Scientific researcher
      Educator/Teacher
      Pharmacist
      Nurse/Nurse practitioner
      Physician assistant
      Allied health professional
      Other
      Competency Area: 
      Professionalism
      Patient Care and Procedural Skills
      Medical Knowledge
      Practice-based Learning and Improvement
      Interpersonal and Communication Skills
      Systems-based Practice
      Topic Area: 
      Diabetes and Glucose Metabolism
      Lipid Disorders and Fatty Liver Diseases
      Health Disparities
      Nutrition
      Obesity
      Pediatric Endocrinology
      Level of Outcomes: 
      Level 1 (Participation)
      Level 2 (Satisfaction)
      Level 3A (Learning: Declarative Knowledge (Knows))
      Level 3B (Learning: Procedural Knowledge (Knows How))
      Activity summary
      Available credit: 
      • 7.50 ABIM MOC
      • 7.50 AMA PRA Category 1 Credits
      • 7.50 CME Certificate of Participation
      Course opens: 
      03/31/2017
      Course expires: 
      03/31/2018
      Rating: 
      Average: 5 (1 vote)
      5

      Program Chairs

      John L. Leahy, MD; Univ of Vermont Coll of Med
      Carol H. Wysham, MD; Rockwood Clin/Univ of Washington Sch of Med

      Presenters

      Silva A. Arslanian, MD; Children's Hosp of Pittsburgh of UPMC
      Linda A. Barbour, MD; Univ of Colorado Sch of Med
      Richard M. Bergenstal, MD; HealthPartners Inst
      Lawrence Blonde, MD; Ochsner Med Ctr
      Kenneth Cusi, MD; Univ of Florida
      Robert H. Eckel, MD; Univ of Colorado Sch of Med
      Irl B. Hirsch, MD; Univ of Washington Med Ctr
      Silvio E. Inzucchi, MD; Yale Sch of Med
      Leigh Perreault, MD; Univ of Colorado Sch of Med
      Richard E. Pratley, MD; Florida Hosp. Translational Res Inst for Metabolism and Diabetes
      Willy M. Valencia, MD, MSc; Univ of Miami

      DISCLOSURE POLICY

      The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

      The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

      The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

      Richard M. Bergenstal, MD: Board Member, Abbott Laboratories

      Lawrence Blonde, MD: Consultant, GlaxoSmithKline, Intarcia Therapeutics, Inc.; Consultant, Investigator, and Speaker, AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC; Investigator, Lexicon Pharmaceuticals, Inc.

      Kenneth Cusi, MD: Consultant and/or Research Support, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Octeta Therapeutics, LLC, Zydus Pharmaceuticals, Inc.

      Robert H. Eckel, MD: Consultant, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC; Researcher, Ionis Pharmaceuticals, Inc.; Independent Contractor (incl. contracted research), uniQure Inc.

      Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Intarcia Therapeutics, Inc., Roche Diagnostics, Valeritas, Inc.

      Silvio E. Inzucchi, MD: Ad Hoc Consultant, Merck & Co., Inc., Janssen Pharmaceuticals, Inc.; Clinical Trial Executive Committee Member, AstraZeneca; Clinical Trial Steering Committee Member, Sanofi‐Aventis US, LLC; Data Monitoring Committee Member, Novo Nordisk Inc.; Publishing Committee Member, Boehringer Ingelheim Pharmaceuticals, Inc.

      John L. Leahy, MD: Advisory Group Member, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC

      Leigh Perreault, MD: Advisory Board Member, Consultant, and/or Speaker, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Merck & Co., Inc., Novo Nordisk Inc., Orexigen Therapeutics, Inc., Pfizer Inc., Sanofi‐Aventis US, LLC

      Richard E. Pratley, MD: Consultant, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc.; Consultant and Speaker, AstraZeneca; Consultant and Research Grant, Lexicon Pharmaceuticals, Inc., Lilly USA, LLC, Merck & Co., Inc., Takeda Pharmaceuticals U.S.A., Inc.; Consultant, Honoraria, Research Grant, and Speaker, Novo Nordisk Inc.; Research Grant, Sanofi‐Aventis US, LLC

      Carol H. Wysham, MD: Advisory Group Member, Investigator, and Speaker, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly & Co., Janssen Pharmaceuticals, Inc., Sanofi‐Aventis US, LLC; Investigator and Speaker, Novo Nordisk Inc.

      The following faculty reported no relevant financial relationships: Silva A. Arslanian, MD; Linda A. Barbour, MD; Willy M. Valencia, MD, MSc

      The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

      CME & MOC

      The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Maintenance of Certification (MOC):

      By completing this activity, you are eligible to earn a maximum of 7.5 American Board of Internal Medicine (ABIM) Medical Knowledge MOC points.

      In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

      1. Provide your board-certification information in your educational profile

      Review & Edit your Profile

      Available Credit

      • 7.50 ABIM MOC
      • 7.50 AMA PRA Category 1 Credits
      • 7.50 CME Certificate of Participation

      Accreditation Period

      Course opens: 
      03/31/2017
      Course expires: 
      03/31/2018
      Subscribe to RSS - Session Recording